Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
about
Optimal management of muscle-invasive bladder cancer - a reviewBladder cancer in the elderly patient: challenges and solutionsSystemic, perioperative management of muscle-invasive bladder cancer and future horizons.Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?DNA Repair Pathway Alterations in Bladder Cancer.Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder.Trimodality therapy in bladder cancer: who, what, and when?[Organ-sparing treatment of bladder cancer].Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer.Adenovirus-mediated downregulation of the ubiquitin ligase RNF8 sensitizes bladder cancer to radiotherapy.Urothelial carcinoma management in elderly or unfit patients.Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerBladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experienceLong term disease free survival with multimodal therapy in small cell bladder cancer.SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder CancerTargeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells.Developing proteomic biomarkers for bladder cancer: towards clinical application.New advances in genitourinary cancer: evidence gathered in 2014.Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit.Emerging drugs for urothelial (bladder) cancer.Incidental Dose to Pelvic Nodes in Bladder-Only Radiotherapy: Is It Clinically Relevant?Current Concepts in the Management of Muscle Invasive Bladder Cancer.Tackling non-muscle invasive bladder cancer in the clinic.Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy.Long-term single-institute experience with trimodal bladder-preserving therapy with proton beam therapy for muscle-invasive bladder cancer.Robot-assisted brachytherapy of the bladder with long distance support using video conferencing.Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysisTrimodality therapy in variant urothelial carcinoma: choose wisely.Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.Genomic characterization of response to chemoradiation in urothelial bladder cancer.Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.Bladder cancer and the National Cancer Data Base: New insight or misinformation?Can bladder preservation therapy come to the center stage?Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline.Should we care more about SPARE?Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.
P2860
Q26784038-1D54B695-C197-4F1B-B7F4-B28BB9483380Q28082782-B38FC522-C298-43EA-9C12-4EE7EC038675Q30240816-BC036853-DC0B-47AC-8BC7-05E4305E0A6EQ30277868-F70088DD-B6E9-4512-8D92-75F1BA49527BQ33578560-CE46F1F8-F376-4483-BCC5-BB3DCBCB7914Q33607945-271DB35F-CE27-40E4-8A1D-1D2A848497C0Q34993621-769BFF8D-D904-4616-8CA4-F00116050445Q35603639-05214987-4A63-4CCC-B9FD-44A7A604D2B4Q35733590-AD8F6051-A70F-466D-A064-7834DC7941D9Q36000786-312F21FF-F782-43A2-A1B4-2E3F690C0BE4Q36448064-D8CB8985-5B77-4248-AD0C-2F8CE3DC997EQ36962466-C84E20D9-9B31-427A-AC87-235ED2D3D9CCQ37030514-581FFB5D-E084-4258-BA1A-F1AE8D13398BQ37053820-9D990DD7-350E-437B-82F3-99D1DB1C0223Q37146457-B4E2F252-7814-4FBF-A543-D5CBD9E5B4ACQ37340577-0D1E060A-8108-4A21-8046-4EE1E4D49B22Q37475193-4A2588C5-D7C0-4521-BAE1-0142BAD330D2Q37530329-9A9E3972-1227-4240-BCC5-3E44906BDAACQ37530349-19A8B5D0-CC7E-4487-AFC6-8BC9B2479E54Q37693418-EB61367F-AE88-4321-97E3-9963999D6490Q38511509-B1C76D30-81D5-4FFF-AC6C-7631D67F08E5Q38557894-18AF1042-15F4-48EA-B2CD-EE4CB7FAC5A8Q38615547-3280676C-D918-4C2B-80B6-14F1EA718C40Q38677414-3C08AAFF-4087-4500-8D53-31F0C9DEF984Q38974743-BB7C5758-90D4-4265-B4BC-C1E87CDDC288Q39105784-D0281821-5E8B-4CDB-8D07-E1AC7846310FQ39209020-B459C42E-FDFD-4FE9-8D91-19BC98653985Q40436642-C2723916-23B4-4BEA-BB20-DCB31AF6A2C8Q40543032-401B5CED-2D0B-48FD-9355-1C149CD8955BQ41689138-8E1FD630-A095-440B-A422-5FF70DA3A005Q41998977-B73A7AB0-C3FA-4E25-B892-0C02949140B5Q42353501-C0FEAB60-56A2-4B3F-B1C1-4EC7C951DA97Q43756593-8E6D36F0-6D52-43AF-BABB-7B224C01219BQ44338887-57DC3AA7-5734-498A-A6CA-33880190C43CQ47570039-122A6CFD-15E8-4D02-B047-89920FF5D4A0Q48234885-7C14BB98-78EC-4212-A96B-91DD7E088C63Q49684699-52D28BB9-057B-492F-9D68-FCC3F0405FA5Q49954597-7AC505AC-409D-45A0-B4BF-D35382407B61Q50073046-86285B46-F6F5-4ED2-9514-3FC7C91742AAQ53070572-6DEB7146-3958-42BC-9946-73FA4B6FA448
P2860
Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Long-term outcomes in patients ...... 3, 9506, 9706, 9906, and 0233.
@ast
Long-term outcomes in patients ...... 3, 9506, 9706, 9906, and 0233.
@en
Long-term outcomes in patients ...... 3, 9506, 9706, 9906, and 0233.
@nl
type
label
Long-term outcomes in patients ...... 3, 9506, 9706, 9906, and 0233.
@ast
Long-term outcomes in patients ...... 3, 9506, 9706, 9906, and 0233.
@en
Long-term outcomes in patients ...... 3, 9506, 9706, 9906, and 0233.
@nl
prefLabel
Long-term outcomes in patients ...... 3, 9506, 9706, 9906, and 0233.
@ast
Long-term outcomes in patients ...... 3, 9506, 9706, 9906, and 0233.
@en
Long-term outcomes in patients ...... 3, 9506, 9706, 9906, and 0233.
@nl
P2093
P2860
P356
P1476
Long-term outcomes in patients ...... 3, 9506, 9706, 9906, and 0233.
@en
P2093
Anthony L Zietman
Daniel Hunt
Donald S Kaufman
Jason A Efstathiou
Michael P Hagan
Niall M Heney
Raymond H Mak
William J Tester
William U Shipley
P2860
P304
P356
10.1200/JCO.2014.57.5548
P407
P577
2014-11-03T00:00:00Z